http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 06:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28C%29%284%29/26643470.html Mon, 15 Jun 2026 06:00:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Press+Releases/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.</p> <p align="justify">Detailed results of the vote for the election of directors are set out below:</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: http://www.streetinsider.com/Globe+Newswire/Fennec+Announces+Results+of+Annual+Meeting/26630301.html Wed, 10 Jun 2026 16:30:00 -0400 FENC FRX O.21047090 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337